Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge - Wikidata - awgldk - TriplyDB

Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge

Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge

http://www.wikidata.org/entity/Q35076828

about

Animal models for Ebola and Marburg virus infections Current ebola vaccines Emerging targets and novel approaches to Ebola virus prophylaxis and treatment Ebolavirus vaccines for humans and apes Host gene targets for novel influenza therapies elucidated by high-throughput RNA interference screens Circumventing antivector immunity: potential use of nonhuman adenoviral vectors Ebola virus vaccines: an overview of current approaches Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?Ebola and Marburg virus vaccines.Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus Ethics review of studies during public health emergencies - the experience of the WHO ethics review committee during the Ebola virus disease epidemic.New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model.Augmented replicative capacity of the boosting antigen improves the protective efficacy of heterologous prime-boost vaccine regimens.First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002)Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.Species D human adenovirus type 9 exhibits better virus-spread ability for antitumor efficacy among alternative serotypes.Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles.A novel and simple method for rapid generation of recombinant porcine adenoviral vectors for transgene expression Optimized adenovirus-antibody complexes stimulate strong cellular and humoral immune responses against an encoded antigen in naive mice and those with preexisting immunity.Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine The number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes Dissociation of skeletal muscle for flow cytometric characterization of immune cells in macaques Fighting Ebola: A Window for Vaccine Re-evaluation?Potential vaccines and post-exposure treatments for filovirus infections.First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors.Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization.A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors.Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.Native and engineered tropism of vectors derived from a rare species D adenovirus serotype 43.Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine.Adenovirus-vectored drug-vaccine duo as a potential driver for conferring mass protection against infectious diseases.Immune recognition of gene transfer vectors: focus on adenovirus as a paradigm.Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?.Immunology of protection from Ebola virus infection.Adenovirus-vectored Ebola vaccines.

P2860

Q21131118-0D9F22E2-DD45-4B34-9CEF-D15A47CBE6C8 Q21534720-6C6E9A66-8AEE-4980-A2C3-71E54EB16A71 Q24597625-70BD08FF-4B6E-4DBF-B357-3BF1F70B4212 Q24631696-7006F403-A642-48C8-8005-EEB6E57E3E5B Q26852062-BD151FE3-55EC-4103-AF6A-460CFFD0F88C Q26995655-B39B94EA-4613-4CB6-A0A7-0CB3E9D30B10 Q26999232-8038ACC3-0C24-4AEA-91B7-9F14066B52D5 Q28485505-B3CB3047-6633-4950-BFF9-52607C3E5DC0 Q29994671-F012161F-3758-4394-9173-95AB2FEE5617 Q30234637-61B8D041-8075-4C61-8B8B-44ED5AD7D749 Q30724121-997537BC-84B5-45F4-93C3-07126D248C4A Q33837161-F6A37131-AA91-4A0D-B4FC-E10E3B24337C Q33868760-1C6E6E06-A35E-4AA6-800B-6DD16D05B3FE Q33887812-2D627F39-6EE9-46AE-8B25-92E3F1CBEA6E Q34209026-C567F9AB-803D-4ADA-B387-C69433E0065E Q34437167-991E3E02-D43A-41B4-828F-BF05BD075F61 Q34463780-FBE820D3-BE12-4562-A498-B5B64E4A9405 Q35087653-1EEF98D8-2048-4FED-8313-29CDAA622CF5 Q35202880-463825A0-48B3-4556-8DA9-3DCBBF666924 Q35641856-B04EF44E-5F6C-4EB3-9802-86A64BE071A0 Q35666180-FE7A068E-1C9F-42C9-B529-F37BA0D0E0AD Q35917496-4CBE2844-907B-41D2-82AC-F1200CDC1971 Q36023055-92E28821-0D11-4BF4-8D6D-320F85382A0C Q36157283-B3F654FC-4164-43AB-B00D-ADAB71D716D6 Q36247762-62B42577-9443-4329-B678-CDEDB5981FC1 Q36404178-D1E66514-5294-49AF-B13E-5667EB43F96F Q36495581-CD5DDEED-C8F5-4C52-BCFC-6E5DC2D55A52 Q36559772-89C03CF3-71BB-46E5-AC6A-FB6A970EB892 Q36674446-1B8E5BA2-F54F-4B55-AD42-376CA307978E Q36735672-D3D53ABE-3081-42B1-B1AD-405D2E62D76E Q36768279-4F4AAE6C-E46E-442F-8489-6D205270A95B Q37277825-4F3B0083-D2AB-4A57-8896-76CB08889829 Q37619767-BBE86404-B683-470F-860A-7CC4A84A7F34 Q37627897-2324C331-6C73-4BAF-8CEA-DB9A110C7208 Q37951524-3A70E879-E932-4F5D-BB12-5999FBF89BC0 Q38008337-E9D69E74-DFC3-4D76-B257-4C32EBE799F0 Q38096490-095A8AC7-B9BA-47C2-A822-2CBA236C3F10 Q38284700-4CDB7DE9-F5DF-4090-AE6D-575BA3A89BB2 Q38462668-C23F2FA3-0652-4F23-955F-081361F53A5E Q38569831-C9037747-F68F-4B35-AA94-0C5532651FD7

P2860

Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge

http://www.wikidata.org/entity/Q35076828

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Recombinant adenovirus serotyp ...... s against ebolavirus challenge

@ast

Recombinant adenovirus serotyp ...... s against ebolavirus challenge

@en

type

label

Recombinant adenovirus serotyp ...... s against ebolavirus challenge

@ast

Recombinant adenovirus serotyp ...... s against ebolavirus challenge

@en

prefLabel

Recombinant adenovirus serotyp ...... s against ebolavirus challenge

@ast

Recombinant adenovirus serotyp ...... s against ebolavirus challenge

@en

P1433

Q35076828-E8598D34-054D-4B3E-B4C8-FE66A55E9B32

P1476

Q35076828-5B8ACE25-350E-4C04-8847-D02764C7904E

P2093

Q35076828-2144DDC1-8B55-4865-9194-E98E8D437F79

Q35076828-24D1DD6B-F963-4714-AD43-27C494455CD9

Q35076828-2ED1C685-CF7E-4FC0-B59F-9DB50315C6FB

Q35076828-45AF81E8-C9DA-4E00-A25B-03588473715E

Q35076828-6165A516-1EA8-4BDB-BF6A-1DEC9DAED3D7

Q35076828-7FC23063-F8F3-413E-9C74-36AC47705A21

Q35076828-81CCD64C-61DE-428C-A871-DF8E934545CB

Q35076828-C725E5FF-2AB9-48EB-BEE3-672503537691

Q35076828-CC6D7C66-D707-443B-85C8-6F15C2B5B3D2

Q35076828-EDF3078F-D7A4-410A-BC8E-CC79DBF75B91

P2860

Q35076828-04704714-2DCF-4D4F-A2CC-75201C924B7D

Q35076828-06E6C4EA-DB28-4578-9BEE-13C54BE79496

Q35076828-0BAD24AA-C4A0-4BAD-BC09-5E9359980A86

Q35076828-142CAA6E-CCA9-43EA-829B-CAD03348491A

Q35076828-17C40868-D99C-4916-A2EF-EAF70B9E411E

Q35076828-1CAB83E0-7602-4650-83AF-06CBC6F1025A

Q35076828-23384EE1-B5E0-4872-B75C-89E0D0929802

Q35076828-261D2AC7-6D34-45B6-8F0D-1BE0880D543E

Q35076828-2AFCC317-04A5-4AEC-A68B-356C4A0E370F

Q35076828-305DE046-D058-4E1C-A4B0-75845FF2452C

P304

Q35076828-751CC0AF-6CD9-40C9-A328-BE050D28ED19

P31

Q35076828-3709E0D7-0E73-4D0B-92F2-62F5A63ADD44

P356

Q35076828-8AE843A1-FB18-44AC-AE2B-8BBCF58A17C6

P407

Q35076828-0F0C3DEC-F4EC-4098-A5E5-EBAED10243C4

P433

Q35076828-9D4FB0D9-7FA7-4179-BC4E-477495B79FC2

P478

Q35076828-1962D4AB-76A2-4888-9DE2-C4BC12346C46

P50

Q35076828-09778846-F8AF-428E-AE4F-E81DA7623BB1

Q35076828-0CC02AF0-F215-45B6-A96A-975981A07A19

Q35076828-7C4CD70B-A1FD-40E2-ABD1-86267009DDE2

Q35076828-95EA69D5-8021-45CE-AAEE-4E858A9C18E0

Q35076828-A153D3ED-D011-4907-A796-F2D9257D61A9

Q35076828-C41BDA40-89C8-4BD7-9510-D3E36D98E36F

P577

Q35076828-96E0AA84-482C-4EEE-9B2A-23DBCFA09FDB

P698

Q35076828-BE800694-96C5-4DF9-88F8-D9A24A76000B

P921

Q35076828-B086D731-8687-4223-83C3-D652855A157F

P932

Q35076828-5410DD3F-F38E-4657-A8FA-849D045E701A

P356

P1433

Journal of Virology

P1476

Recombinant adenovirus serotyp ...... s against ebolavirus challenge

@en

P2093

Clement Asiedu

http://www.w3.org/2001/XMLSchema#string

Daphne Stanley

http://www.w3.org/2001/XMLSchema#string

Jenny Hendriks

http://www.w3.org/2001/XMLSchema#string

Jerome Custers

http://www.w3.org/2001/XMLSchema#string

Joan Geisbert

http://www.w3.org/2001/XMLSchema#string

Jort Vellinga

http://www.w3.org/2001/XMLSchema#string

Maria Grazia Pau

http://www.w3.org/2001/XMLSchema#string

Mario Roederer

http://www.w3.org/2001/XMLSchema#string

Michael Bailey

http://www.w3.org/2001/XMLSchema#string

Nancy J Sullivan

http://www.w3.org/2001/XMLSchema#string

P2860

Clustal W and Clustal X version 2.0

Development of a preventive vaccine for Ebola virus infection in primates

Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses

Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells.

A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).

Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054)

Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates

Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity

P304

4222-4233

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.02407-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P50

Peter B. Jahrling

Joshua C Johnson

Thomas W Geisbert

P577

2011-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21325402

http://www.w3.org/2001/XMLSchema#string

P921

P932

3126236

http://www.w3.org/2001/XMLSchema#string